Boston-based pharmaceutical company Ratio Therapeutics has announced the completion of a $50 million Series B financing round to advance its targeted radiotherapies for cancer treatment. The funding brings Ratio’s total raised capital to more than $90 million since its launch in 2021. Investors including Schusterman and Duquesne as well as the Center for Technology Licensing at Cornell University participated in the round.
Ratio’s technology platforms Trillium and Macropa leverage alpha particles to develop novel radiopharmaceuticals to treat and monitor cancers. The platforms address the challenges of delivery, safety and efficacy typically associated with radiopharmaceuticals, according to the company. Its new funding will help Ratio expand the applications of these proprietary solutions.
Additionally, Ratio will invest in developing its fibroblast activation protein-alpha targeted therapeutic which aims to treat various solid-tumor cancers. The company hopes to move this candidate into clinical trials by the end of 2024.
